Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EXELIXIS, INC.EXEL · Entity 3386 | EVP, Prod Dev & Med Aff &CMO | April 03, 2023 | April 06, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EXELIXIS, INC.
Report date April 03, 2023 · Filed April 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 307,654 |
Reported balance
After 2023-04-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-04-03 · Grant · Acquired 82,566 · Balance 307,654 F1: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on May 15, 2024 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each May 15th until fully vested. F3: Includes 246,383 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.
F2: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on May 15, 2024 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each May 15th until fully vested.
F3: Includes 246,383 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Mural Oncology plc
Report date December 05, 2025 · Filed December 05, 2025
Section 16 reporting ended · disclosed 2025-12-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-12-05 transaction · row 1
1 source rowRow 1 · 2025-12-05 · Disposition to issuer · Disposed 84,727 · Balance 0 F1: Pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"), as of December 5, 2025 (the "Effective Time"). F2: Includes the disposition of 71,509 unvested restricted stock units ("RSUs"). Pursuant to the Agreement, as of the Effective Time each RSU held by the Reporting Person that was outstanding as of immediately prior to the Effective Time (whether or not vested) was automatically cancelled and converted into the right to receive an amount equal to the Scheme Consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.61 · Expires 2033-12-13 | Direct | 0 |
Reported balance
After 2025-12-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-05 · Disposition to issuer · Disposed 135,604 · Balance 0 F3: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.43 · Expires 2035-03-02 | Direct | 0 |
Reported balance
After 2025-12-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-12-05 · Disposition to issuer · Disposed 65,000 · Balance 0 F3: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"), as of December 5, 2025 (the "Effective Time").
F2: Includes the disposition of 71,509 unvested restricted stock units ("RSUs"). Pursuant to the Agreement, as of the Effective Time each RSU held by the Reporting Person that was outstanding as of immediately prior to the Effective Time (whether or not vested) was automatically cancelled and converted into the right to receive an amount equal to the Scheme Consideration.
F3: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 05, 2025 Filed Dec 5, 2025 08:45 UTC | Mural Oncology plc MURA · Entity 72153 | Disposition to issuerStock Option (right to buy) · Derivative | 65,000 | Not disclosed Strike: $3.43 | Not disclosed |
DisclosureSEC source: 0001193125-25-308745 · ownership.xml · derivative · entry 3 Goodman Vicki L · CIK 0001901477 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 65,000 shares Expires 2035-03-02 F3 · price: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. F3 · derivative.exercise_date: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. Read SEC document |
| December 05, 2025 Filed Dec 5, 2025 08:45 UTC | Mural Oncology plc MURA · Entity 72153 | Disposition to issuerStock Option (right to buy) · Derivative | 135,604 | Not disclosed Strike: $3.61 | Not disclosed |
DisclosureSEC source: 0001193125-25-308745 · ownership.xml · derivative · entry 2 Goodman Vicki L · CIK 0001901477 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 135,604 shares Expires 2033-12-13 F3 · price: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. F3 · derivative.exercise_date: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. Read SEC document |
| December 05, 2025 Filed Dec 5, 2025 08:45 UTC | Mural Oncology plc MURA · Entity 72153 | Disposition to issuerOrdinary Shares | 84,727 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-308745 · ownership.xml · nonDerivative · entry 1 Goodman Vicki L · CIK 0001901477 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"), as of December 5, 2025 (the "Effective Time"). F2 · shares: Includes the disposition of 71,509 unvested restricted stock units ("RSUs"). Pursuant to the Agreement, as of the Effective Time each RSU held by the Reporting Person that was outstanding as of immediately prior to the Effective Time (whether or not vested) was automatically cancelled and converted into the right to receive an amount equal to the Scheme Consideration. F1 · price: Pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"), as of December 5, 2025 (the "Effective Time"). F2 · price: Includes the disposition of 71,509 unvested restricted stock units ("RSUs"). Pursuant to the Agreement, as of the Effective Time each RSU held by the Reporting Person that was outstanding as of immediately prior to the Effective Time (whether or not vested) was automatically cancelled and converted into the right to receive an amount equal to the Scheme Consideration. Read SEC document |
| November 10, 2025 Filed Nov 10, 2025 18:30 UTC | Mural Oncology plc MURA · Entity 72153 | SaleOrdinary Shares | 5,036 | $2.08 | $10,474.88 |
DisclosureSEC source: 0001193125-25-274765 · ownership.xml · nonDerivative · entry 1 Goodman Vicki L · CIK 0001901477 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,727 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 14, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement that includes a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on December 22, 2023, and the sale does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 71,509 unvested restricted stock units. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 16:47 UTC | Mural Oncology plc MURA · Entity 72153 | GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0000950170-25-033764 · ownership.xml · derivative · entry 2 Goodman Vicki L · CIK 0001901477 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Ordinary Shares · 65,000 shares Expires 2035-03-02 F3 · derivative.exercise_date: This option was granted on March 3, 2025. The option is scheduled to vest with respect to 25% of the underlying ordinary shares on March 1, 2026 and the remaining 75% of the underlying ordinary shares shall vest in 12 equal quarterly installments thereafter, subject to the reporting person's continued services with the Issuer. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 16:47 UTC | Mural Oncology plc MURA · Entity 72153 | GrantOrdinary Shares | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-033764 · ownership.xml · nonDerivative · entry 1 Goodman Vicki L · CIK 0001901477 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,763 F1 · shares: Consists of ordinary shares issuable under 35,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one ordinary share upon vesting. The RSUs are scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of March 1, 2025, subject to the reporting person's continued service with the Issuer. F2 · balance_after: Includes 54,763 unvested restricted stock units. Read SEC document |
| February 24, 2025 Filed Feb 25, 2025 16:03 UTC | Mural Oncology plc MURA · Entity 72153 | SaleOrdinary Shares | 13,186 | $3.89 | $51,293.54 |
DisclosureSEC source: 0000950170-25-026609 · ownership.xml · nonDerivative · entry 1 Goodman Vicki L · CIK 0001901477 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,763 F1 · kind: Represents shares automatically sold by the Reporting Person pursuant to a Rule 10b5-1 trading arrangement that was entered into by the Reporting Person on October 24, 2024. F2 · balance_after: Includes 54,763 unvested restricted stock units. Read SEC document |
| November 07, 2024 Filed Nov 8, 2024 16:02 UTC | Mural Oncology plc MURA · Entity 72153 | SaleOrdinary Shares | 5,069 | $3.33 | $16,879.77 |
DisclosureSEC source: 0000950170-24-124041 · ownership.xml · nonDerivative · entry 1 Goodman Vicki L · CIK 0001901477 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,949 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 14, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement that includes a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on December 21, 2023, and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.33 to $3.35. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes 54,763 unvested restricted stock units. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 16:30 UTC | Mural Oncology plc MURA · Entity 72153 | GrantStock Option (right to buy) · Derivative | 135,604 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0000950170-23-071113 · ownership.xml · derivative · entry 2 Goodman Vicki L · CIK 0001901477 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,604 Underlying: Ordinary Shares · 135,604 shares Expires 2033-12-13 F2 · derivative.exercise_date: This option was granted on December 14, 2023. The option is scheduled to vest with respect to 25% of the underlying ordinary shares on November 6, 2024 and the remaining 75% of the underlying ordinary shares shall vest in 12 equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 16:30 UTC | Mural Oncology plc MURA · Entity 72153 | GrantOrdinary Shares | 73,018 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-071113 · ownership.xml · nonDerivative · entry 1 Goodman Vicki L · CIK 0001901477 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,018 F1 · shares: Consists of ordinary shares issuable under 73,018 restricted stock units ("RSUs"). Each RSU represents the right to receive one ordinary share upon vesting. The RSUs are scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of November 6, 2023, subject to the reporting person's continued service with the Issuer. Read SEC document |
| April 03, 2023 Filed Apr 6, 2023 00:24 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 82,566 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-23-000037 · wf-form4_168074064086550.xml · nonDerivative · entry 1 Goodman Vicki L · CIK 0001901477 · EVP, Prod Dev & Med Aff &CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 307,654 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on May 15, 2024 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each May 15th until fully vested. F3 · balance_after: Includes 246,383 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 15, 2023 Filed Feb 18, 2023 02:38 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 17,299 | $18.08 | $312,765.92 |
DisclosureSEC source: 0000939767-23-000022 · wf-form4_167668786613786.xml · nonDerivative · entry 1 Goodman Vicki L · CIK 0001901477 · EVP, Prod Dev & Med Aff &CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,088 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded January 4, 2022. F2 · balance_after: Includes 163,817 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| January 04, 2022 Filed Jan 7, 2022 01:02 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 7,613 | $19.18 | $146,017.34 |
DisclosureSEC source: 0000939767-22-000004 · wf-form4_164151735117017.xml · nonDerivative · entry 2 Goodman Vicki L · CIK 0001901477 · EVP, Prod Dev & Med Aff &CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,387 F4 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded on the Transaction Date. Read SEC document |
| January 04, 2022 Filed Jan 7, 2022 01:02 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-22-000004 · wf-form4_164151735117017.xml · nonDerivative · entry 1 Goodman Vicki L · CIK 0001901477 · EVP, Prod Dev & Med Aff &CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as follows: 26,315 shares subject to the restricted stock unit award vested on the Transaction Date; 59,868 shares subject to the restricted stock unit award will vest on February 15, 2023; 59,869 shares subject to the restricted stock unit award will vest on February 15, 2024; and 51,974 shares subject to the restricted stock unit award will vest on each of February 15, 2025 and February 15, 2026. F3 · balance_after: Includes 223,685 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.